Q2 EPS Forecast for Viking Therapeutics Lowered by Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Equities researchers at B. Riley dropped their Q2 2025 EPS estimates for shares of Viking Therapeutics in a note issued to investors on Thursday, April 24th. B. Riley analyst M. Mamtani now expects that the biotechnology company will post earnings of ($0.43) per share for the quarter, down from their previous forecast of ($0.33). B. Riley has a "Buy" rating and a $96.00 price target on the stock. The consensus estimate for Viking Therapeutics' current full-year earnings is ($1.56) per share. B. Riley also issued estimates for Viking Therapeutics' Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.76) EPS, FY2026 earnings at ($2.41) EPS, FY2027 earnings at ($3.48) EPS and FY2028 earnings at ($2.92) EPS.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.07). During the same period last year, the business posted ($0.26) earnings per share.

Other analysts have also recently issued reports about the stock. The Goldman Sachs Group initiated coverage on shares of Viking Therapeutics in a report on Tuesday, April 8th. They issued a "neutral" rating and a $30.00 price target on the stock. Raymond James upped their target price on shares of Viking Therapeutics from $122.00 to $125.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. Maxim Group decreased their price target on Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Scotiabank started coverage on Viking Therapeutics in a research note on Thursday, February 13th. They set a "sector outperform" rating and a $102.00 price objective on the stock. Finally, Piper Sandler decreased their target price on Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating for the company in a research report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $89.50.

Viking Therapeutics Stock Down 2.6 %

Shares of VKTX opened at $24.99 on Monday. Viking Therapeutics has a 52-week low of $18.92 and a 52-week high of $81.86. The firm has a market cap of $2.81 billion, a price-to-earnings ratio of -24.99 and a beta of 0.84. The business's 50 day moving average is $26.47 and its two-hundred day moving average is $40.34.

Insiders Place Their Bets

In other news, Director Sarah Kathryn Rouan bought 1,240 shares of the firm's stock in a transaction on Monday, March 31st. The stock was purchased at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the transaction, the director now owns 1,240 shares in the company, valued at approximately $29,946. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 4.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Viking Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in VKTX. Blue Trust Inc. increased its position in Viking Therapeutics by 75.9% in the 4th quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 309 shares during the period. YANKCOM Partnership acquired a new position in shares of Viking Therapeutics during the fourth quarter valued at $33,000. Parallel Advisors LLC raised its stake in shares of Viking Therapeutics by 64.8% during the first quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 536 shares in the last quarter. FIL Ltd raised its stake in shares of Viking Therapeutics by 116.8% during the fourth quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 648 shares in the last quarter. Finally, NBC Securities Inc. lifted its holdings in Viking Therapeutics by 222,100.0% in the first quarter. NBC Securities Inc. now owns 2,222 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 2,221 shares during the period. 76.03% of the stock is currently owned by institutional investors and hedge funds.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.